BIODESIX INC (BDSX) Stock News
NASDAQ:BDSX - Nasdaq - US09075X1081 - Common Stock - Currency: USD
BDSX Latest News, Press Relases and Analysis
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will...
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: RVTY
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet...
BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biodesix (NASDAQ:BDSX) just reported results for the second quarter of 2024.Bio...
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology
Mentions: BIO
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue...
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton,...
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will...
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
Grew full-year revenue to an estimated $71.3 million, an increase of 45%...
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
Grew full-year revenue to an estimated $71.3 million, an increase of 45%
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance...
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance
Biodesix Announces Third Quarter 2024 Results and Highlights
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6%...
Biodesix Announces Third Quarter 2024 Results and Highlights
Biodesix to Participate in Three Investor Conferences in November
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease,...
Biodesix to Participate in Three Investor Conferences in November
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
Biodesix to Present at Two Investor Conferences in September
BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q2 2024
BDSX stock results show that Biodesix beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Biodesix Announces Second Quarter 2024 Results and Highlights
Biodesix to Present at Canaccord Genuity’s 44th Annual Growth Conference
Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024
